Wagner Lars M, Crews Kristine R, Stewart Clinton F, Rodriguez-Galindo Carlos, McNall-Knapp Rene Y, Albritton Karen, Pappo Alberto S, Furman Wayne L
Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Pediatr Blood Cancer. 2008 Feb;50(2):201-7. doi: 10.1002/pbc.21280.
Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan.
伊立替康在儿科肿瘤学中的应用日益广泛。减轻与长期使用伊立替康相关的腹泻可能会降低发病率并提高剂量强度。在本综述中，我们讨论了关于这种毒性的发病机制以及潜在的易感遗传因素的已知情况。我们全面总结了有关现有预防和治疗策略的文献，并报告了在各种儿科试验中接受治疗的51例患者使用头孢菌素预防的相关数据。这种方法在儿童中是可行的，并且能够耐受更高剂量的长期伊立替康。
